Articles tagged with: Revlimid
Headline, News »
A statistical analysis of two Phase 3 trials found relapsed and refractory multiple myeloma patients who achieved complete remission and very good partial response to Revlimid and dexamethasone combination treatment had higher overall survival rates and longer times to disease progression compared to patients who only achieved partial response.
The analysis also showed that patients’ response to Revlimid and dexamethasone improved over time with continuous treatment.
The authors of the analysis therefore suggested continuing treatment in patients who achieved partial response as long as possible to achieve best outcome.
They…
News »
Revlimid Granted Approval For Multiple Myeloma In Japan – Celgene announced last week that Revlimid (lenalidomide) has been approved for the treatment of relapsed and refractory multiple myeloma in combination with dexamethasone (Decadron) in Japan. Revlimid will be available through Revmate, a proprietary distribution program. For more information, please read the Celgene press release.
Immunomedics Doses First Multiple Myeloma Patient With Milatuzumab-Doxorubicin Combination – Immunomedics has dosed the first patient in a Phase 1/2 study of its milatuzumab-based treatment for multiple myeloma. This treatment has doxorubicin (Adriamycin), a chemotherapy drug, bound to milatuzumab, an antibody. It will be evaluated for its efficacy as a treatment for relapsed and refractory multiple myeloma patients. For more information, please see the Immunomedics press release and the clinical trial description.
ImmunoGen And Sanofi-Aventis Announce Beginning Of Phase 1 Trial Of Potential New Myeloma Treatment – ImmunoGen Inc. and Sanofi-Aventis announced the initiation of a Phase 1 clinical trial of SAR650984, an antibody that targets cancer cells. In preclinical testing, SAR650984 was found to have anti-cancer effects, and is now being investigated as a treatment for relapsed and refractory multiple myeloma as well as other blood cancers. For more information, please refer to the ImmunoGen press release.
Headline, News »
Preliminary results from a Phase 1 clinical trial suggest that everolimus (RAD001), in combination with Revlimid (lenalidomide), may have potential in the treatment of relapsed/refractory multiple myeloma. The findings were presented on June 4 at the American Society of Clinical Oncology (ASCO) annual meeting.
Everolimus is marketed by Novartis under the brand name Afinitor for the treatment of advanced kidney cancer and under the name Zortress to prevent kidney transplant rejection. Everolimus is currently being investigated as a potential treatment for multiple…
Headline, News »
Treatment of newly diagnosed multiple myeloma patients with a combination of cyclophosphamide (Cytoxan), Velcade (bortezomib), and dexamethasone (Decadron) (abbreviated CyBorD) appears to be effective and safe. The findings were presented June 5 in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.
The study compared CyBorD with Revlimid (lenalidomide)-dexamethasone treatment (abbreviated RD) and cyclophosphamide-Revlimid-dexamethasone treatment (abbreviated CRD). The results of the Phase 2 trials indicate that RD and CyBorD treatment were similar in efficacy and safety. CRD, however, was not as effective…
Headline, News, Resources »
This article describes a myeloma patient’s experience participating in a clinical trial. It is part of a series of articles intended to help clarify the clinical trial process.
In August 2008, Phil Brabbs was diagnosed with smoldering myeloma, which most physicians do not treat until symptoms begin and the disease progresses to multiple myeloma. After more than a year of physicians carefully reviewing his blood work, Phil’s smoldering myeloma progressed to multiple myeloma, and his physicians wanted to begin treatment.
Phil’s doctor suggested that he participate in a clinical trial…
Headline, News »
Results of two Phase 1b clinical trials suggest that panobinostat in combination with Velcade (bortezomib) or Revlimid (lenalidomide) and dexamethasone (Decadron) is effective and well-tolerated in patients who are resistant (refractory) to previous multiple myeloma treatment. The findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago in early June.
“There are novel therapies that have improved the outcome, literally doubled the survival, of patients with myeloma. Despite these incredible advances, inevitably most patients relapse, and so we need [new] novel…
Headline, News »
Preliminary results from two ongoing clinical trials suggest that elotuzumab in combination with either Velcade (bortezomib) or Revlimid (lenalidomide) plus low-dose dexamethasone (Decadron) is effective and well-tolerated in patients who have relapsed or are resistant (refractory) to previous myeloma treatment. The findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Elotuzumab is a new drug being developed by Facet Biotech and Bristol-Myers Squibb as a potential treatment for multiple myeloma. It selectively targets proteins that are on the…
Headline, News, Resources »
This article describes a myeloma patient’s experience participating in a clinical trial. It is part of a series of articles intended to help clarify the clinical trial process.
Don was diagnosed with multiple myeloma in 2004. At the age of 69 and despite living with a cancer that attacks his bones, Don inspires fellow myeloma patients by running in marathons. He has completed three marathons so far this year, is running in one tomorrow, and plans on participating in three to four more marathons just this year. Additionally, Don maintains…
Headline, News »
Significant advances have been made in the treatment of multiple myeloma since the introduction of thalidomide (Thalomid), Revlimid (lenalidomide), and Velcade (bortezomib). Combinations of these “novel agents” have significantly improved response rates and survival rates with better safety profiles than stem cell transplants, leading researchers and patients to ask whether the use of transplants is necessary given the efficacy of the novel agents.
Two studies that are investigating whether novel agents are as effective, or possibly more effective, than an autologous stem cell transplant (ASCT) were…
Featured, Headline, News »
Advances in the development of multiple myeloma drugs have had a profound impact on the way the disease is treated. Given the efficacy and relative safety of these novel agents, studies are being conducted to determine whether they may be as effective, or possibly even more effective, than an autologous stem cell transplant (ASCT). Two such studies were presented June 6 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Results from the two studies suggest that ASCT (in which a patient’s own stem cells are…